Nutriband Announces USPTO Notice of Allowance for Commercial Brand Name Trademarks for Its Abuse-Deterrent Fentanyl Transdermal System
Nutriband Inc. received a USPTO Notice of Allowance for commercial brand name trademarks for its abuse-deterrent fentanyl transdermal patch incorporating AVERSA™ technology. The company is preparing preapproval regulatory submissions for the FDA, EMA, and international agencies, with peak annual U.S. sales potential estimated between $80-200 million.